Key facts
- This page summarizes James A. Geraghty's Form 4 filing for Orchard Therapeutics plc.
- 3 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 24 Jan 2024, 17:29.
James A. Geraghty - 24 Jan 2024 Form 4 Insider Report for Orchard Therapeutics plc
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 24 Jan 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 24 Jan 2024, 17:29:38 UTC
- Prior SEC filing
- 29 Jun 2023
- Next SEC filing
- 07 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Frank Thomas, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
James A. Geraghty filed Form 4 for Orchard Therapeutics plc on 24 Jan 2024.
Change
- Previous filing in this sequence was filed on 29 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ORTX
transaction
Ordinary Shares
Disposed to Issuer
- Transaction value
- Shares
- -44,391
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 24 Jan 2024
- Ownership
- Direct
- Footnotes
- F1, F2, F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ORTX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -46,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 24 Jan 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 46,000
- Exercise price
- $0.4750
- Footnotes
- F1, F2, F3, F4
ORTX
transaction
Derivative
Stock Option (Right to Buy)
Disposed to Issuer
- Transaction value
- $0
- Shares
- -105,000
- Change %
- -100%
- Price
- $0.000000*
- Shares after
- 0
- Date
- 24 Jan 2024
- Ownership
- Direct
- Underlying class
- Ordinary Shares
- Underlying amount
- 105,000
- Exercise price
- $0.4950
- Footnotes
- F1, F2, F3, F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
James A. Geraghty is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 4 footnotes
Footnote F1
The ordinary shares, nominal value GBP 0.10 per share (the "Ordinary Shares") may be represented by American Depositary Shares ("ADSs"), each of which currently represents ten Ordinary Shares.
Footnote F2
On January 24, 2024, Kyowa Kirin Co., Ltd., a Japanese joint stock company ("KKC") acquired all outstanding Ordinary Shares of Orchard Therapeutics plc, a public limited company incorporated in England and Wales (the "Company"), by means of a scheme of arrangement under Part 26 of the UK Companies Act 2006 (the "Scheme of Arrangement"). At the effective time of the Scheme of Arrangement, each outstanding Ordinary Share of the Company was exchanged for an amount equal to (a) $1.60 in cash, without interest (the "Cash Consideration"), and (b) one contractual contingent value right (each, a "CVR"), each representing the right to receive a contingent payment of $0.10 in cash, without interest, if a certain milestone is achieved, pursuant to the Contingent Value Rights Agreement between KKC and a rights agent mutually agreeable to the Company and KKC.
Footnote F3
(continued) In addition, each ADS of the Company was exchanged for an amount equal to (a) $16.00 in cash (less certain Orchard ADS Fees pursuant to the terms of the deposit agreement, dated as of November 2, 2018, as amended, by and among the Company, Citibank, N.A., as depositary, and all holders and beneficial owners of Orchard ADSs issued thereunder), and (b) 10 CVRs. The transaction is more fully described in the Company's definitive proxy statement filed with the Securities and Exchange Commission on November 16, 2023.
Footnote F4
Pursuant to the Transaction Agreement dated as of October 5, 2023 by and between KKC and the Company, these options were cancelled in exchange for (i) an amount in cash equal to the excess of the Cash Consideration over the per share exercise price of such options and (ii) one CVR.